Pharmaceutical Business review

Soar BioDynamics introduces new screening tool for prostate cancer

According to the company, Soar Dynamic Screening demonstrates a new approach to healthcare by providing men a detailed analysis of their prostate health based on several factors beyond the industry-standard prostate-specific antigen (PSA) test. The tool also analyzes other important variables including a man’s personal health history, PSA trends over time and comparisons with up to a million case studies.

Soar Dynamic Screening for the prostate uses individual profile data, test results and cutting-edge technology to deliver personalized analysis, the company noted.

Through a web-based tool, men enter the results of their PSA test history and personal information such as height, weight and health history. This information is compared with up to a million case studies and outcomes from other men with various prostate conditions. Finally, the system may suggest a medical detective process for doctors and their patients in their efforts to detect non-cancerous prostate conditions and improve prostate cancer screening, the company said.

Soar provides men with 20 opportunities annually to analyze their prostate health data, enabling ongoing, up-to-date analyses when needed to support men and their doctors’ efforts to conduct medical detective processes. Soar does not collect personally identifiable information, maximizing patient privacy, the company added.